These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 10778993

  • 1. Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine.
    Fanciulli M, Bruno T, Giovannelli A, Gentile FP, Di Padova M, Rubiu O, Floridi A.
    Clin Cancer Res; 2000 Apr; 6(4):1590-7. PubMed ID: 10778993
    [Abstract] [Full Text] [Related]

  • 2. Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells.
    Fanciulli M, Valentini A, Bruno T, Citro G, Zupi G, Floridi A.
    Oncol Res; 1996 Apr; 8(3):111-20. PubMed ID: 8823807
    [Abstract] [Full Text] [Related]

  • 3. Correspondence re: M. Fanciulli et al., Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence fo lonidamine. Clin. Cancer Res., 6: 1590-1597, 2000.
    Kaplan O.
    Clin Cancer Res; 2000 Oct; 6(10):4166-7. PubMed ID: 11051272
    [No Abstract] [Full Text] [Related]

  • 4. Glucose metabolism in adriamycin-sensitive and -resistant LoVo human colon carcinoma cells.
    Fanciulli M, Bruno T, Castiglione S, Del Carlo C, Paggi MG, Floridi A.
    Oncol Res; 1993 Oct; 5(9):357-62. PubMed ID: 8038456
    [Abstract] [Full Text] [Related]

  • 5. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
    Lelong-Rebel I, Brisson C, Fabre M, Bergerat JP, Rebel G.
    Anticancer Res; 2008 Oct; 28(1A):55-68. PubMed ID: 18383825
    [Abstract] [Full Text] [Related]

  • 6. Intracellular P-glycoprotein in multidrug resistant tumor cells.
    Arancia G, Molinari A, Calcabrini A, Meschini S, Cianfriglia M.
    Ital J Anat Embryol; 2001 Oct; 106(2 Suppl 1):59-68. PubMed ID: 11729998
    [Abstract] [Full Text] [Related]

  • 7. Biological characterization of multidrug-resistant human colon carcinoma sublines induced/selected by two methods.
    Yang LY, Trujillo JM.
    Cancer Res; 1990 Jun 01; 50(11):3218-25. PubMed ID: 2334917
    [Abstract] [Full Text] [Related]

  • 8. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells.
    Floridi A, Paggi MG, D'Atri S, De Martino C, Marcante ML, Silvestrini B, Caputo A.
    Cancer Res; 1981 Nov 01; 41(11 Pt 1):4661-6. PubMed ID: 7306982
    [Abstract] [Full Text] [Related]

  • 9. A search for multidrug resistance modulators: the effects of retinoids in human colon carcinoma cells.
    Bartolini G, Orlandi M, Papi A, Ammar K, Guerra F, Ferreri AM, Rocchi P.
    In Vivo; 2006 Nov 01; 20(6A):729-33. PubMed ID: 17203756
    [Abstract] [Full Text] [Related]

  • 10. Energy metabolism of adriamycin-sensitive and -resistant Ehrlich ascites tumor cells.
    Miccadei S, Fanciulli M, Bruno T, Paggi MG, Floridi A.
    Oncol Res; 1996 Nov 01; 8(1):27-35. PubMed ID: 8704284
    [Abstract] [Full Text] [Related]

  • 11. [Relationship between multidrug resistance in human colon carcinoma LoVo/Adr cell line and intracellular calcium ion concentration].
    Ma Q, Zhang ZS, Zhang YL, Lai ZS.
    Ai Zheng; 2002 Aug 01; 21(8):846-9. PubMed ID: 12478890
    [Abstract] [Full Text] [Related]

  • 12. Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells.
    Scala S, Pacelli R, Iaffaioli RV, Normanno N, Pepe S, Frasci G, Genua G, Tsuruo T, Tagliaferri P, Bianco AR.
    Cancer Res; 1991 Sep 15; 51(18):4898-902. PubMed ID: 1893380
    [Abstract] [Full Text] [Related]

  • 13. Further characterization of two distinct adriamycin-resistant sublines from LoVo human colon carcinoma cells.
    Yang LY, Trujillo JM, Su YZ.
    Anticancer Res; 1992 Sep 15; 12(2):473-9. PubMed ID: 1349796
    [Abstract] [Full Text] [Related]

  • 14. Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism.
    Floridi A, Bruno T, Miccadei S, Fanciulli M, Federico A, Paggi MG.
    Biochem Pharmacol; 1998 Oct 01; 56(7):841-9. PubMed ID: 9774146
    [Abstract] [Full Text] [Related]

  • 15. Mitochondria, hexokinase and pyruvate kinase isozymes in the aerobic glycolysis of tumor cells.
    Petrucci D, Cesare P, Colafarina S.
    Ital J Biochem; 1997 Sep 01; 46(3):131-41. PubMed ID: 9442422
    [Abstract] [Full Text] [Related]

  • 16. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
    Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES, Mayer LD.
    Cancer Res; 2000 Jun 01; 60(11):2964-72. PubMed ID: 10850444
    [Abstract] [Full Text] [Related]

  • 17. [Treatment and post-treatment with lonidamine in human colon carcinoma HT-29 cell line].
    Fuchs AG.
    Medicina (B Aires); 2008 Jun 01; 68(1):13-22. PubMed ID: 18416315
    [Abstract] [Full Text] [Related]

  • 18. Growth inhibition by rhein and lonidamine of human glioma cells in vitro.
    Floridi A, Gentile FP, Bruno T, Castiglione S, Zeuli M, Benassi M.
    Anticancer Res; 1990 Jun 01; 10(6):1633-6. PubMed ID: 2285235
    [Abstract] [Full Text] [Related]

  • 19. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
    Pan L, Tong Y, Jin Y, Zhou S, Zhang Y, Yang X, Mao N.
    Chin Med J (Engl); 2001 Sep 01; 114(9):929-32. PubMed ID: 11780384
    [Abstract] [Full Text] [Related]

  • 20. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
    Ramachandran C, Wellham LL.
    Anticancer Res; 2003 Sep 01; 23(3B):2681-90. PubMed ID: 12894558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.